Abstract：
BACKGROUND: Erythropoietin has an angiogenic effect on the retina and might increase the risk of retinopathy of prematurity (ROP).
METHODS: This retrospective cohort study included infants born at 22 to 27 weeks\' gestation between 2008 and 2018 who were admitted to neonatal intensive care units (NICUs). We compared mortality and morbidities between infants who received erythropoietin and those who did not.
RESULTS: Among 18,955 livebirth infants, this study included 16,031 infants, among which 14,373 infants received erythropoietin. The risk of ROP requiring treatment was significantly higher in the erythropoietin group than in the control group (33% vs. 26%; aOR 1.50 [95% CI 1.28-1.76]). On the other hand, the erythropoietin group had lower risks of death and necrotizing enterocolitis.
CONCLUSIONS: This study with a large sample size found that erythropoietin use was associated with increased risk of ROP requiring treatment, while being associated with reductions in deaths and NEC.
METHODS: This retrospective cohort study included infants born at 22 to 27 weeks\' gestation between 2008 and 2018 who were admitted to neonatal intensive care units (NICUs). We compared mortality and morbidities between infants who received erythropoietin and those who did not.
RESULTS: Among 18,955 livebirth infants, this study included 16,031 infants, among which 14,373 infants received erythropoietin. The risk of ROP requiring treatment was significantly higher in the erythropoietin group than in the control group (33% vs. 26%; aOR 1.50 [95% CI 1.28-1.76]). On the other hand, the erythropoietin group had lower risks of death and necrotizing enterocolitis.
CONCLUSIONS: This study with a large sample size found that erythropoietin use was associated with increased risk of ROP requiring treatment, while being associated with reductions in deaths and NEC.
摘要：
背景：促红细胞生成素对视网膜具有血管生成作用，并可能增加早产儿视网膜病变（ROP）的风险。
方法：这项回顾性队列研究包括2008年至2018年间出生在妊娠22至27周的新生儿重症监护病房（NICU）的婴儿。我们比较了接受促红细胞生成素的婴儿和未接受促红细胞生成素的婴儿的死亡率和发病率。
结果：在18,955名出生婴儿中，这项研究包括16,031名婴儿，其中14,373名婴儿接受促红细胞生成素治疗.促红细胞生成素组需要治疗的ROP风险明显高于对照组(33%vs.26%；aOR1.50[95%CI1.28-1.76]）。另一方面,促红细胞生成素组的死亡和坏死性小肠结肠炎风险较低.
结论：这项大样本研究发现，使用促红细胞生成素与需要治疗的ROP风险增加有关，同时与减少死亡和NEC有关。
方法：这项回顾性队列研究包括2008年至2018年间出生在妊娠22至27周的新生儿重症监护病房（NICU）的婴儿。我们比较了接受促红细胞生成素的婴儿和未接受促红细胞生成素的婴儿的死亡率和发病率。
结果：在18,955名出生婴儿中，这项研究包括16,031名婴儿，其中14,373名婴儿接受促红细胞生成素治疗.促红细胞生成素组需要治疗的ROP风险明显高于对照组(33%vs.26%；aOR1.50[95%CI1.28-1.76]）。另一方面,促红细胞生成素组的死亡和坏死性小肠结肠炎风险较低.
结论：这项大样本研究发现，使用促红细胞生成素与需要治疗的ROP风险增加有关，同时与减少死亡和NEC有关。
